Fortrans, an osmotic laxative containing Polyethylene Glycol 3350 with electrolytes, is used for the therapeutic purpose of: bowel cleansing. The primary benefit is colon preparation, which is required before certain diagnostic and surgical procedures.

The core use of Fortrans is for pre-procedure colon preparation, specifically for: colonoscopy, barium enema X-ray exams, or colon surgery. This preparation is utilized to cleanse the colon (bowel) to achieve a clear view of the colon lining, which is necessary for the examination.

Bowel evacuation is required to help allow for the examination to take place.

This medication is not intended for managing general constipation or other chronic digestive symptoms.

Quick Fact: Relief for Pre-Procedure Bowel Preparation (The medication is used to prepare the bowel for examination.)

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Profile: Who Can and Cannot Use Фортранс?

Фортранс (Macrogol 4000/PEG-Electrolytes) is a specialized prescription preparation with strict eligibility criteria defined by regulatory authorities to ensure safe use for pre-procedural bowel cleansing. Use is primarily established for adults and, in some regions, adolescents aged 15 and older.

---

Absolute Contraindications

The medicine must not be used in patients with the following conditions, as they represent absolute prohibitions:

• Gastrointestinal Obstruction (known or suspected) or paralytic ileus.
• Bowel Perforation or risk of perforation.
• Toxic Colitis or Toxic Megacolon.
• Gastric Retention or severe inflammatory bowel disease.
• Known Hypersensitivity to Macrogol (PEG) or any of the formulation's excipients.

---

Conditional Use and Restrictions

Use requires extreme caution and medical supervision in certain populations:

• Age: Use is often contraindicated in children under 15 years, and older adults (geriatric patients) require close monitoring due to increased risk of fluid and electrolyte imbalances.
• Comorbidity: Patients with Renal Impairment, Severe Heart Failure, a history of Cardiac Arrhythmias, or a history of Seizures require careful assessment.
• Status: Pre-existing dehydration must be fully corrected prior to administration. The preparation is designated Pregnancy Category C by some regulators, requiring use only if clearly needed.

Interactions with other medicines and products

The interaction profile for Fortrans (Macrogol 4000 with electrolytes) is defined by its function as a high-volume bowel preparation agent, which causes rapid gastrointestinal transit. This physical action is the basis for a documented pharmacokinetic interaction: co-administration with all other oral medicinal products may result in a transient reduction in absorption.

This reduction in exposure is classified as a clinically significant risk for drugs with a narrow therapeutic index, such as digoxin, antiepileptics (anticonvulsants), and coumarins (anticoagulants). To mitigate the potential for decreased efficacy, official regulatory documentation requires that all other oral medications must be administered separately from the Fortrans solution.

A separate interaction constraint involves preparation: the solution must not be directly mixed with starch-based thickeners. This results in a physicochemical incompatibility leading to a dangerous loss of viscosity. Regulatory bodies note this interaction significantly increases the aspiration risk for patients with dysphagia (swallowing difficulties).

Additionally, a pharmacodynamic interaction exists with medications that affect fluid and electrolyte balance, such as diuretics. Co-administration may reinforce their effects, thereby increasing the documented potential for electrolyte disturbances. The official profile contains no known systemic interactions involving CYP enzymes or drug transporters.

How Фортранс Works

---

Macrogol 4000: Osmotic Action and Fluid Dynamics

The action of Фортранс is initiated by the non-absorbed polymer Macrogol 4000, which operates through a physicochemical osmotic mechanism. Macrogol 4000 has no affinity for biological receptors, enzymes, or ion channels; its primary interaction is the formation of hydrogen bonds with water molecules. This process prevents the normal reabsorption of fluid, thereby creating a strong osmotic gradient that traps a substantial volume of water within the entire intestinal lumen. This establishes the necessary high-volume state for the subsequent high-volume evacuation.

---

Physiomechanical Triggering of Propulsive Motility

The large, retained fluid volume physically distends the colon walls, mechanically stimulating the peristaltic reflex within the enteric nervous system. This distension acts as the primary signal, triggering a forceful, whole-bowel contraction that rapidly and propulsively moves the liquid contents. This is a purely mechanical modulation of gastrointestinal motility, leading to a rapid, high-volume propulsion of intestinal contents.

---

️ Electrolytes and Homeostasis Modulation

Electrolyte salts are combined with the active polymer to ensure the final solution remains isosmotic with blood plasma. While these salts do not enhance the propulsive action, their presence ensures the solution maintains isotonicity. This mechanism prevents the large-volume fluid shift required for the flush from pathologically affecting the body’s fluid balance, thus mitigating net fluid and ion shifts across the intestinal wall.

Фортранс (Macrogol 4000/PEG-ES) is used exclusively via the oral route as a high-volume solution for complete pre-procedural bowel cleansing. The usage framework is defined to ensure the intended lavage.

---

Administration Guidelines

The total prescribed adult dose requires consuming 4 liters of the reconstituted solution. This preparation is structured around a steady rate of ingestion, typically requiring a consumption rate of 250 mL every 10 to 15 minutes until the full volume has been ingested.

Administration is scheduled using two primary patterns: the single-day regimen where the entire 4 liters are taken the evening before the procedure, or the generally utilized split-dose regimen, dividing the volume between the evening and the following morning. Crucially, the completion of the full course must occur a minimum of 2 to 4 hours prior to the medical procedure to ensure sufficient time for bowel clearance.

Preparation and Conditions

The drug is supplied as a powder, which must be fully dissolved in the specified volume of water, usually one sachet per liter. Proper use necessitates adherence to a clear liquid diet during the administration period. This acute use course is not intended for long-term or cyclic regimens. Use in pediatric patients requires dose determination and direct oversight from a medical professional.

Research Evidence / Overview of Studies for Фортранс (Fortrans)

Evidence for use in Bowel Cleansing Before Procedures

Research examined the preparation process using Fortrans in patients requiring bowel preparation before internal examinations, such as colonoscopy. The available research primarily consists of short-term Randomized Controlled Trials (RCTs) and various other controlled studies. Researchers monitored outcomes related to functional imbalance, measuring the clarity of the bowel lining using standardized scoring systems. Studies focused mainly on adult populations, and research highlights changes measured during the study period, with findings describing patterns observed in the studies regarding the attainment of pre-defined cleansing quality levels.

Comparative Research Against Other Preparations

Comparative effectiveness studies were applied in observational settings evaluating daily-life functioning during the preparation phase. Research examined Fortrans against other preparation agents or alternative dosing methods, such as the split-dose regimen. These studies monitored outcomes related to physical discomfort and the time required to complete the preparation. Studies explored the measured outcomes when using Fortrans versus other methods and described patterns related to the time it took to complete the preparation process, contributing to the broader evidence landscape.

Evidence in Specific Patient Populations

Research has also been evaluated in smaller, more specific patient groups, including older adults and individuals with conditions such as a history of chronic constipation. Studies explored outcomes reflecting daily functioning during the short preparation window in these subgroups. Findings from some studies indicate patterns where factors like pre-existing conditions were associated with reported differences in the experience of the preparation. Research describes how symptoms evolved in the observed populations, and findings indicate that specific patient characteristics may influence the tolerability and completion rates of the regimen.

Durability and Long-Term Research

Because Fortrans was observed in studies focusing on a single, acute event (bowel cleansing), the follow-up durations were limited in most of the research conducted. Studies focused almost entirely on the measured outcomes of the procedure itself and the immediate post-procedure period. As a result, long-term effects are not fully established. There is limited information for long-term outcomes regarding any extended-duration effects on patient health or the durability of the preparation's outcome for future procedural scheduling.

What is Still Uncertain About Fortrans Research

The existing research provides context but not individual predictions. Sample sizes were modest in some of the subgroup analyses, meaning the data for certain groups remain insufficient to draw broad conclusions. Evidence quality varies across studies due to differences in how "successful cleansing" was defined and measured. The research highlights what is known—and what is still uncertain—emphasizing that study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019
2. The safety and effects of high- and low-volume polyethylene glycol bowel preparation methods before colonoscopy on bowel cleanliness: a systematic review and meta-analysis
3. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US Multi-Society Task Force on Colorectal Cancer

Common questions about Фортранс (FAQ)

Q: What is Фортранс (Forlax) used for?

Фортранс (also known by its active ingredient, Macrogol 4000 or Polyethylene Glycol), is a type of osmotic laxative used to treat constipation in adults and children over 8 years of age. It works by retaining water in the stool, making the feces softer and easier to pass. It is also commonly used for bowel cleansing prior to medical procedures requiring a clean colon, such as a colonoscopy or radiological examination.

---

Q: How should I take Фортранс?

Фортранс is typically dissolved in water and taken orally. The dose depends on whether it is being used to treat chronic constipation or for full bowel cleansing.

• For Constipation: The dose is usually one or two sachets per day, taken preferably in the morning. The dosage should be adjusted to produce a regular soft stool.
• For Bowel Cleansing: A higher dose is required, usually involving taking a number of sachets (e.g., 4 liters of solution) over a specific time period on the day before the procedure. It is essential to follow the instructions provided by your doctor or the specific regimen outlined in the product leaflet exactly for bowel preparation.

---

Q: How long does it take for Фортранс to work?

For the treatment of constipation, the effects of Фортранс may not be immediate, but it generally starts to work within 24 to 48 hours after the first dose.

When used for bowel preparation (colon cleansing), the effect is much more rapid. Bowel movements typically begin within 1 to 2 hours of starting the high-dose solution. The full bowel cleansing process can take several hours until the output is clear liquid.

---

Q: What are the common side effects of Фортранс?

Like many medications, Фортранс can cause side effects, though not everyone experiences them. The most common side effects are often related to the gastrointestinal tract and include:

• Abdominal pain or discomfort
• Bloating
• Nausea
• Diarrhea (expected when used for bowel cleansing)

Less common side effects can include hypersensitivity reactions like rash, itching, or swelling. If you experience signs of a severe allergic reaction, seek medical attention immediately.

---

Q: Can I take Фортранс during pregnancy or while breastfeeding?

• Pregnancy: Data suggests that Macrogol 4000 (the active ingredient in Фортранс) has minimal systemic absorption, making it less likely to pose a risk. However, it is generally recommended to use it only if clearly necessary and under the guidance of a doctor.
• Breastfeeding: The product is generally considered compatible with breastfeeding because of its very low absorption into the body. However, as with any medication, you should consult your healthcare provider before use while nursing.

Official Storage and Disposal Requirements

Regulatory documentation defines specific rules for storing and disposing of Fortrans (Macrogol 4000) to ensure product stability and safety. This information is derived from official governmental labeling and guidelines.

Storage Scope	Requirement
Temperature	Store the powder below 25 C or 30 C; Do not freeze.
Protection	Keep the unopened sachets in the original outer packaging to protect the product from moisture.
Reconstituted Solution Stability	The prepared solution should be used promptly. If necessary, it must be stored in a refrigerator (2 C to 8 C) for no more than 24 hours.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Do not dispose of expired or unused product in household trash or via wastewater (sinks or toilets). Return it to a pharmacy or designated pharmaceutical waste collection point for proper disposal.